CU20210061A7 - Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer - Google Patents

Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer

Info

Publication number
CU20210061A7
CU20210061A7 CU2021000061A CU20210061A CU20210061A7 CU 20210061 A7 CU20210061 A7 CU 20210061A7 CU 2021000061 A CU2021000061 A CU 2021000061A CU 20210061 A CU20210061 A CU 20210061A CU 20210061 A7 CU20210061 A7 CU 20210061A7
Authority
CU
Cuba
Prior art keywords
domain
alpha
vaccine composition
mica
cancer
Prior art date
Application number
CU2021000061A
Other languages
English (en)
Inventor
Soumya Badrinath
Kai Wucherpfenning
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of CU20210061A7 publication Critical patent/CU20210061A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

<p>La presente invención proporciona una composición de vacuna que comprende, como un componente inmunogénico, un péptido que comprende o consiste de un dominio alfa 3 de MIC, en donde el péptido comprende o consiste de la secuencia de aminoácidos de SEQ ID NO: 3 o SEQ ID NO: 4 o una secuencia que es al menos 90 porciento idéntica a las mismas. Esta composición de vacuna provoca una respuesta inmune contra el dominio alfa 3 de MIC.</p>
CU2021000061A 2015-12-04 2016-12-05 Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer CU20210061A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US201662422454P 2016-11-15 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Publications (1)

Publication Number Publication Date
CU20210061A7 true CU20210061A7 (es) 2022-02-04

Family

ID=57590885

Family Applications (2)

Application Number Title Priority Date Filing Date
CU2018000050A CU24609B1 (es) 2015-12-04 2016-12-05 Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
CU2021000061A CU20210061A7 (es) 2015-12-04 2016-12-05 Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CU2018000050A CU24609B1 (es) 2015-12-04 2016-12-05 Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic

Country Status (24)

Country Link
US (2) US10993971B2 (es)
EP (1) EP3383426A1 (es)
JP (2) JP7099956B2 (es)
KR (1) KR20180088458A (es)
CN (1) CN108770343A (es)
AU (2) AU2016362597C1 (es)
BR (1) BR112018010705A8 (es)
CA (1) CA3005910A1 (es)
CL (2) CL2018001470A1 (es)
CO (1) CO2018006642A2 (es)
CR (2) CR20180350A (es)
CU (2) CU24609B1 (es)
EA (1) EA201891287A1 (es)
IL (1) IL259490A (es)
MX (2) MX2018006785A (es)
MY (1) MY199248A (es)
NZ (1) NZ742663A (es)
PE (2) PE20181158A1 (es)
PH (1) PH12018501170A1 (es)
RU (2) RU2747296C2 (es)
SG (1) SG11201804597TA (es)
TN (1) TN2018000187A1 (es)
WO (1) WO2017096374A1 (es)
ZA (1) ZA202204223B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773698A1 (en) * 2018-04-03 2021-02-17 Sanofi Ferritin proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
CA2063271A1 (en) 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
AU6909098A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AR022963A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
CA2776272C (en) 2001-10-01 2016-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
CA2589034C (en) 2004-11-02 2016-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
WO2011046842A1 (en) 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
WO2011074573A1 (ja) 2009-12-18 2011-06-23 花王株式会社 メソポーラスシリカ粒子の製造方法
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
AU2012311238A1 (en) * 2011-09-23 2014-04-17 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
BR112014007487A2 (pt) 2011-09-30 2017-04-04 Dana Farber Cancer Inst Inc peptídeos terapêuticos
WO2013117647A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
WO2013158673A1 (en) 2012-04-16 2013-10-24 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
BR112015021576A2 (pt) 2013-03-15 2017-10-10 Dana Farber Cancer Inst Inc peptídeos terapêuticos
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
CN113491766A (zh) * 2014-03-14 2021-10-12 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法

Also Published As

Publication number Publication date
JP2018536002A (ja) 2018-12-06
MY199248A (en) 2023-10-23
MX2018006785A (es) 2018-11-09
CO2018006642A2 (es) 2018-07-10
AU2022201940A1 (en) 2022-04-14
SG11201804597TA (en) 2018-06-28
NZ742663A (en) 2023-02-24
CN108770343A (zh) 2018-11-06
CL2018001470A1 (es) 2018-12-21
CU24609B1 (es) 2022-06-06
IL259490A (en) 2018-07-31
BR112018010705A2 (pt) 2018-11-21
PH12018501170A1 (en) 2019-01-21
CU20180050A7 (es) 2018-11-06
JP7099956B2 (ja) 2022-07-12
BR112018010705A8 (pt) 2019-02-26
PE20230495A1 (es) 2023-03-23
RU2018123307A (ru) 2020-01-13
AU2016362597C1 (en) 2022-05-26
MX2022010194A (es) 2022-09-19
TN2018000187A1 (en) 2019-10-04
PE20181158A1 (es) 2018-07-19
EP3383426A1 (en) 2018-10-10
RU2018123307A3 (es) 2020-04-20
AU2016362597B2 (en) 2022-02-17
ZA202204223B (en) 2023-12-20
US20210299186A1 (en) 2021-09-30
JP2022130623A (ja) 2022-09-06
KR20180088458A (ko) 2018-08-03
CR20230116A (es) 2023-05-05
EA201891287A1 (ru) 2018-11-30
RU2747296C2 (ru) 2021-05-04
US10993971B2 (en) 2021-05-04
CL2021001256A1 (es) 2021-12-31
AU2016362597A1 (en) 2018-06-07
US20180353581A1 (en) 2018-12-13
CA3005910A1 (en) 2017-06-08
CR20180350A (es) 2018-10-02
WO2017096374A1 (en) 2017-06-08
RU2021109510A (ru) 2021-04-16

Similar Documents

Publication Publication Date Title
CY1122142T1 (el) Συνθεσεις που περιλαμβανουν στελεχη του βακτηριου blautia για τη θεραπευτικη αγωγη σπλαγχνικης υπερευαισθησιας
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
UY32457A (es) Vacuna del virus del dengue inactivado
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
MX2018015410A (es) Esteres de oxaborol y sus usos.
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
MY193807A (en) T-cell receptor and uses thereof
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
CL2017001159A1 (es) Composiciones farmacéuticas de larga duración para la hepatitis c
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite